VINC (Vincerx Pharma) Long-Term Debt: $0.00 Mil (As of Mar. 2025)


What is Vincerx Pharma Long-Term Debt?

Vincerx Pharma VINC Long-Term Debt is $0.00 Mil as of Mar. 2025.

Vincerx Pharma's Long-Term Debt for the quarter that ended in Mar. 2025 was $0.00 Mil.

Vincerx Pharma  (OTCPK:VINC) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Vincerx Pharma Long-Term Debt Related Terms

Vincerx Pharma Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Vincerx Pharma's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vincerx Pharma Long-Term Debt Chart

Vincerx Pharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Long-Term Debt
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Vincerx Pharma Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $0.00 Mil mean?
Vincerx Pharma (VINC) has a Long-Term Debt of $0.00 Mil as of Mar. 2025.
Is Vincerx Pharma's Long-Term Debt too high?
Vincerx Pharma's current Long-Term Debt is $0.00 Mil.
How does Vincerx Pharma's Long-Term Debt compare to SYGGF and CNBX?
Vincerx Pharma's Long-Term Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Vincerx Pharma's current Long-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vincerx Pharma stock overvalued right now?
Vincerx Pharma (VINC) has a current Long-Term Debt of $0.00 Mil. The current Long-Term Debt is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Vincerx Pharma (VINC), the current Long-Term Debt is $0.00 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vincerx Pharma Business Description

Address 1825 S. Grant Street, San Mateo, CA, USA, 94402
Vincerx Pharma Inc is a clinical-stage biopharmaceutical company focused on development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The company's activities are conducted in the United States. It focuses on developing, using, manufacturing, commercializing, sublicensing, and distributing a clinical-stage and follow-on small molecule drug program and a preclinical-stage bioconjugation/next-generation ADC platform.